Sale of all interest in assets including contracts, drug application registrations, the 'Plenaxis' trademarks and trade names, patents, know-how, technical information, promotional and marketing materials, customer and supplier lists, marketing studies, product inventory and materials, manufacturing equipment, product records, government authorizations and shares, with royalty on the sale of products containing abarelix in any formulation, including the 'Plenaxis' product formulated in 'Rel-Ease' or similar formulation to treat prostate cancer, abarelix products for injectable suspension, an abarelix product to treat endometriosis including sustained release or depot formulations, and other products under sublicense.

This text describes a legal transaction involving the sale of all assets, patents, and trademarks related to abarelix products by one party to another. The agreement includes specific provisions for royalties on future sales of formulations intended to treat prostate cancer and endometriosis. RoyaltyStat is mentioned as a database used for valuing such intellectual property and license agreements in transfer pricing contexts. Relevance to endometriosis: listed as one indication for abarelix products within a commercial asset sale agreement, though the paper's main focus is financial valuation and corporate transactions.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works